<DOC>
	<DOC>NCT01775761</DOC>
	<brief_summary>The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.</brief_summary>
	<brief_title>A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy, nonsmoking, male and/or female subjects of nonchildbearing potential. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. An ALT or AST measurement &gt;2 times the ULN. 12lead ECG demonstrating QTc &gt;450 msec or a QRS interval &gt;120 msec at Screening. Subjects at increased risk if dosed with moxifloxacin, according to the product label for moxifloxacin. History of risk factors of QT prolongation or torsades de pointes, congenital deafness and family history of sudden death.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Thorough QTc evaluation of tafamidis compared to the effects of moxifloxacin and placebo in healthy volunteers.</keyword>
</DOC>